

Prevalence and Factors Associated with Moderate-to-Severe Anaemia Among Virally Suppressed People with HIV at a Tertiary Hospital in Zambia

Kingsley Kamvuma^{1,2}, Sepiso K. Masenga¹, Benson M. Hamooya¹, Warren Chanda¹, and Sody Munsaka²

¹HAND Research Group, Mulungush University, School of Medicine and Health Sciences, Department of Pathology and Microbiology, Livingstone campus, Zambia

²University of Zambia of Health Science and Medicine, Department of Biomedical Sciences, Lusaka, Zambia

Abstract:

Objective: Anaemia is associated with an increased risk of disease progression and all-cause mortality among HIV-infected individuals, regardless of the type of anaemia, but the magnitude of the risk is greater with more severe anaemia. Although anaemia PLWH has been extensively studied, the focus has primarily been on its prevalence and association with disease progression in untreated or poorly controlled HIV cases. This study aimed to investigate the prevalence, and factors associated with moderate-to-severe anaemia among virally suppressed HIV patients at a tertiary hospital in Zambia.

Methods: We conducted a cross-sectional study of ART treated PLWH for at least 6 months between October 2023 and February 2024 at Livingstone University Teaching Hospital (LUTH). Sociodemographic, clinical, and laboratory were the data collected. Anaemia was defined based on the World Health Organisation (WHO) classification, as haemoglobin concentration lower than normal i.e. <12 g/dl in females and <13 g/dl in males. The primary outcome was moderate-to-severe anaemia defined as haemoglobin level below 10.9 g/dl based World Health Organisation (WHO) classification. Logistic regression was performed to identify factors associated with moderate-to-severe anaemia.

Results: Among 823 participants with viral suppression, the overall prevalence of anaemia and moderate-to-severe anaemia was 29.4% (n=242; 95% confidence interval (CI): 26.3-32.6) and 14.2% (n=117, 95% CI: 11.7-18), respectively. Females exhibited significantly higher odds of moderate-to-severe anaemia compared to males (adjusted odds ratio (AOR) 2.65; 95% confidence interval (CI): 1.21-5.81). Lower lymphocyte count (AOR 0.542; 95% CI: 0.33- 0.90), higher BMI (AOR 1.06; 95% CI: 1.01-1.12), and

Microcytosis (AOR 14.35; 95% CI: 7.33 - 28.08) were associated with increased odds of anaemia. Participants on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens had a higher likelihood of anaemia compared to those on integrase strand transfer inhibitor (INSTI) regimens (AOR 5.16; 95% CI: 1.02- 26.24).

Conclusion: We found a higher prevalence of anaemia and moderate-to-severe anaemia in virally suppressed PLWH, suggesting factors beyond HIV contribute to the persistence of anaemia in this cohort. Female gender, lower lymphocyte count, higher BMI, low mean corpuscular volume, and NNRTI-based ART regimens were independently associated with moderate-to-severe anaemia. Further research is warranted to explain the underlying mechanisms and optimize clinical management to improve outcomes among virally suppressed PLWH.

Key words: PLWH, Viral Suppression, Moderate to Severe Anaemia, ART

Introduction

In the past few decades, significant progress has been made in managing HIV infection, transforming it from a once-devastating disease to a chronic, controllable condition with the advent of effective combinational antiretroviral therapy (ART) [1]. With the implementation of the "95-95-95" strategy, there is a growing trend of People Living with HIV (PLWH) achieving viral suppression [2]. However, despite this progress, PLWH continue to face a numerous health challenges, among which anaemia stands out as a persistent and debilitating complication [3]. The prevalence of anaemia varies across clinical settings. Recent studies suggests that anaemia is associated with an increased risk of disease progression, a heightened inflammatory profile including immune reconstitution inflammatory syndrome (IRIS), incident tuberculosis and all-cause mortality among HIV-infected individuals, regardless of type of anaemia, and the magnitude of the risk is greater with more severe anaemia [4], [5], [6]. Understanding the prevalence and severity of anaemia among latently PLWH is crucial for optimizing patient care in this population.

The pathogenesis of anaemia in virally suppressed PLWH remains unclear. However, sub-optimal chronic inflammation, even in the absence of active viral replication, contributes to disrupted erythropoiesis [7], [8]. Inflammatory cytokines interfere with iron metabolism, impairing red blood cell production [9]. Additionally, malabsorption, chronic bleeding and micronutrient deficiencies particularly in limited resource settings may further contribute to anaemia persistence in PLWH.

As antiretroviral therapy prolongs the lives of PLWH, it becomes essential to gain a comprehensive understanding of the dynamic factors shaping their health needs. Although anaemia PLWH has been extensively studied, the focus has primarily been on its prevalence and association with disease progression in untreated or poorly controlled HIV cases [3], [10]. However, a critical gap exists in understanding the factors contributing to moderate-to-severe anaemia specifically among virally suppressed HIV patients, who represent a growing segment of the HIV population due to improved access to effective ART regimens. Therefore, this study aimed to evaluate the prevalence, and factors

associated with moderate to severe anaemia among virally suppressed people living with HIV.

Materials and Methods

Study design and setting

This was cross-sectional study among virally suppressed (viral load <1000 copies/ml) adult PLWH who had been on ART for at least 6 months or more, between 1st September 2023 and 26th February 2024 at Livingstone University Teaching Hospital (LUTH). LUTH provides ART services (laboratory, pharmacy, clinical evaluation, and counselling) and is the largest referral hospital located in Southern part of Zambia servicing over 2.4 million people.

Eligibility criteria

Following informed consent, we recruited adult PLWH aged 18 years and above who had been receiving ART for ≥ 6 months. In this study, pregnant women, participants with a known history of excessive menstrual bleeding, disorders of haemoglobin synthesis including Sickle cell anaemia and thalassaemia or a malignant neoplasm were excluded.

Sample size

The sample size calculation was conducted using the single population proportion formula. Assumptions: True Population Proportion (P): Due to the absence of previous similar studies in the area, we assumed a proportion of 50%. Precision: We set the desired precision (margin of error) at 0.05. Confidence Level: The confidence level was set at 99%. Population Size: population of 3880 patients receiving antiretroviral therapy (ART) at LUTH, we factored in a 30% contingency to account for any unforeseen variations. As a result of these considerations, the final determined sample size for your study was **823** participants.

Study variables and definitions.

Sociodemographic data, including age, sex, blood pressure, alcohol use, and physical exercise were collected from participants and health records (SmartCare and patient files) using a structured questionnaire and data collection form. Trained research assistants administered the questionnaire and obtained blood samples. In case of clinically abnormal findings, participants were referred to a physician. Blood pressure (using a digital machine- Omron-HEM-7120, USA) was determined by calculating an average of three readings obtained after resting participants for 5 minutes and taking readings one minute apart. The height (cm), weight (kg) and waist circumference were measured using a height measurement chart, digital scale and tape measure, respectively. Anaemia was classified based on the mean cell volume (MCV) values as Microcytosis (<80fl), Normocytosis (80-100fl), and Macrocytosis (>100fl) [11]. Viral suppression was defined as per the Zambia Consolidated Guidelines for Treatment and Prevention of HIV Infection, as consistent adherence to antiretroviral therapy (ART) and achieving a viral load of less than 1,000 copies of HIV RNA per milliliter of blood[12]. Anaemia was defined based on the World Health Organisation (WHO) classification, as haemoglobin concentration lower than normal i.e. <12 g/dl in females and <13 g/dl in males[13].

Primary outcome. The primary outcome Moderate-to-severe anaemia was defined by a haemoglobin concentration of <10.9g/dl based on the WHO classification[13].

Blood samples and measurements

We collected viral load and CD4+ count samples in ethylenediaminetetraacetic acid (EDTA) containers; a Becton Dickson flow cytometer was used to analyse total lymphocyte and CD4 lymphocyte count, while the viral load was analysed using Ampliprep/Taqman 96 PCR analyzer. Haemoglobin (Hgb) values were determined using the hematology analyzer Sysmex XT2000 (Abbott Laboratories Diagnostics Division, USA) and CD4+ T cells were assayed using the BD FACSCOUNT system (Becton Dickenson and Company, California, USA). Biochemical analyses were done on a Pentra C200 and HumaStar 80 clinical chemistry analyzer (Human Diagnostics, Germany) using kits supplied by the manufacturer.

ART regimens

Non-nucleoside reverse transcriptase inhibitor (NNRTI) regimens contained efavirenz (EFV) or nevirapine (NVP) with one of the following nucleoside reverse transcriptase inhibitors (NRTIs): Abacavir and lamivudine/emtricitabine (ABC/XTC) or tenofovir disoproxil fumarate and lamivudine/emtricitabine (TDF/XTC). Protease inhibitor (PI) regimens contained either lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) with one of the following NRTI combinations: ABC/XTC or zidovudine/XTC (AZT/XTC) or TDF/XTC. An integrase strand transfer inhibitor (INSTI) regimen contained Dolutegravir (DTG) with TDF/lamivudine (TDF/3TC).

Statistical analysis

All statistical analyses were conducted using SPSS software version 22. Categorical data were summarized using frequencies and proportions, while continuous variables were summarized using medians and interquartile ranges (IQR) due to non-normal distribution, which was confirmed using Q-Q plots and the Shapiro-Wilk test. The Pearson chi-square test was employed to assess statistically significant associations between categorical variables. Mann–Whitney U test (for two unmatched groups) was used to ascertain a statistical difference between two medians. Logistic regression (univariable and multivariable) was utilized to estimate factors associated with moderate to severe anaemia. Covariates included in the final model were selected based on published evidence and variables found to be statistically significant in univariable analysis. Model fitness was assessed using the Hosmer-Lemeshow goodness-of-fit test, with statistical significance defined as $p < .05$.

Ethical considerations

Ethical approval for the study was obtained on 7th August 2023 from the University of Zambia Biomedical Research Ethics Committee (UNZABREC- REF. REF. NO. 4062-2023). Data was collected between 1st October 2023 and 26th February 2024 at

Livingstone University Teaching Hospital (LUTH). The purpose of the study was explained to all the participants in a language familiar to them, and they provided written informed consent after agreeing to take part in the study. Confidentiality and anonymity was maintained during data collection by ensuring that the data were de-identified.

Reporting format

We adhered to the strengthening the reporting of observational studies in epidemiology (STROBE) guidelines for reporting observational studies. See Supplementary 1 Table for details.

Results

Sociodemographic and clinical characteristics of the study participants.

The study included 823 individuals undergoing ART treatment who had achieved viral suppression. Among them, there was a predominance of women, accounting for 61% (n=502) of the participants. The median age of the participants was 41 years (interquartile range (IQR) 40,54), and the age range (18-79) years. The overall prevalence of anaemia and moderate-to-severe anaemia was 29.4% (n=242; 95% confidence interval (CI): 26.3-32.6) and 14.2% (n=117 95% CI: 11.7-18) respectively. With respect to ART regimens, majority were on NNRTI-based regimens (81%, 660/823, followed by INSTI-based regimens (14.5%, n=118), and PI-based regimens (4.7%, n=38). Furthermore, among the participants, 0.8% (n=4) had active tuberculosis, 6.7% (n=51) were positive for Hepatitis B surface antigens, and 14.4% (n=136) had syphilis infections.

Relationship of anaemia status with demographic and clinical factors

Table 1 shows an analysis of factors associated with moderate-to-severe anaemia. A higher prevalence of moderate-to-severe anaemia observed among females compared

to males (19.7% vs. 5.6%, $p = 0.001$). Additionally, ART regimen was associated with moderate-to-severe anaemia, specifically individuals on non-nucleoside/nucleotide reverse transcriptase inhibitor (NNRTI)-based regimens showing a higher prevalence of moderate-to-severe anaemia compared to those on integrase strand transfer inhibitor (INSTI) regimens (16.2% vs. 5.9% and 5.3% respectively, $p = 0.004$). Laboratory findings also reveal significant associations, with parameters such as low mean corpuscular volume (MCV) or Microcytosis and Low lymphocyte count strongly correlated with moderate-to-severe anaemia ($p < 0.05$). Other variables like physical exercise, alcohol consumption, and comorbidities such as Hepatitis B Surface antigen, hypertension, and tuberculosis infection show no significant associations with moderate-to-severe anaemia among our study participants

Table 1. Sociodemographic, and clinical factors according to anaemia status				
Characteristics	Moderate to severe anaemia, n (%)			P-value
	Total (823)	Yes (14.2%, n=117)	No (85.8%, n=706)	
Age in years, m	823	42 (40, 48)	41 (40, 54)	0.429
Sex				0.001
<i>Male</i>	321	18 (5.6)	303 (94.4)	
<i>Female</i>	502	99 (19.7)	403 (80.3)	
Regimen				0.004
<i>INSTI</i>	118	7 (5.9)	111 (94.1)	
<i>PI</i>	39	2 (5.3)	36 (94.7)	
<i>NNRTI</i>	667	107 (16.2)	553 (83.8)	
HBsAg				0.177
<i>Yes</i>	51	4 (7.8)	47 (92.2)	
<i>No</i>	705	47 (6.7)	658 (93.3)	
Hypertension				0.482
<i>yes</i>	76	8 (10.5)	68 (89.5)	
<i>No</i>	447	68 (15.2)	379 (74.8)	
TB				0.403
<i>yes</i>	4	0 (0)	4 (100)	
<i>No</i>	514	76 (14.8)	438 (75.2)	
Syphilis				0.152
<i>yes</i>	136	14 (10.3)	122 (89.7)	
<i>No</i>	687	103 (14.9)	584 (75.1)	
Microcytosis				<0.001
<i>Yes</i>	66	39 (59.1)	27 (40.9)	
<i>No</i>	446	36 (8.1)	410 (91.9)	
Duration ART mo, m(IQR)				0.019
<i>Year 1</i>	72	7 (9.7)	65 (90.3)	
<i>Year 2</i>	95	6 (6.3)	89 (93.7)	
<i>Year 3</i>	50	9 (18)	41 (82)	
<i>4 years and more</i>	297	54 (18.2)	243 (81.8)	
CD4+ t (cells/mL) m(IQR)	823	492 (461, 877)	518 (372, 877)	0.310
BMI kg/m²,m(IQR)	823	22.7 (4.7, 5.6)	21.8 (4.3, 5.3)	0.74
Viral load Copies/uL	823	20 (0.0, 27)	20 (0.0, 47)	0.160
Lymphocytes(109 cells/L), m(IQR)	488	1.86 (1.5, 2.0)	2.12 (1.6, 2.6)	0.002
Monocytes (109 cells/L), m(IQR)	488	0.32 (0.21, 0.51)	0.38 (0.29, 0.50)	0.986

Values are presented as median (m) and Interquartile range (IQR) ±standard deviation for the continuous variables and frequency (percentage) for the categorical variables. mo: months
eGFR: estimated glomerular filtration rate, MCV: mean corpuscular volume, ALT: Alanine aminotransferase, TB: Tuberculosis, HBsAg: Hepatitis B Surface antigen FBS: Fasting blood sugar, VL: Viral load, ESR: erythrocyte sedimentation rate, NNRTI=non-nucleoside/nucleotide reverse transcriptase inhibitor (EFV=efavirenz and NVP=Nevirapine), PI=protease inhibitor (LPV/r=lopinavir/ritonavir and

ATV/r=atazanavir/ritonavir), INSTI=integrase strand transfer inhibitor (DTG=dolutegravir), NRTI=nucleotide reverse transcriptase inhibitor.
--

Relationship between study variables and Outcome status (Moderate to Severe Anaemia)

The graphs illustrates the distribution of median values stratified by the outcome status in our study cohorts. Clinical variables such as Duration on ART in months, Mean corpuscular volume, Absolute lymphocyte count levels showed significant differences when their medians were compared with outcome variable moderate to severe anaemia. BMI, CD4+ count and Viral load levels did not show significant difference between the two groups (see figure 1). Figure 2 shows the prevalence of moderate to severe anaemia across sex, ART regimen, type of anaemia, and physical exercise engagement among PLWH. Prevalence of anaemia was significantly higher among females participants, those with RBC microcytosis based on MCV values and individuals on NNRTI $P < 0.05$.




Figure 1: Stratification of clinical variables by anaemia status (Moderate to Severe anaemia). BMI Body Mass Index, VL Viral Load, ART Antiretroviral therapy, MCV Mean Cell Volume, mo months, ns not significant, ** significant, **** Pvalue <0.001




Figure 2: Illustrates the prevalence of Moderate to Severe Anaemia based on Sex, ART Regimen and Type of Anaemia. PI Protease Inhibitor, INSTI Intragrase Strand Transfer Inhibitor, NNRTI Non nucleotide Reverse Transcriptase Inhibitor, MCV Mean Corpuscular Volume

Logistic regression analysis of factors associated with moderate-to-severe anaemia

The univariable analysis revealed significant correlations between various factors and the odds ratio (OR) of moderate to severe anaemia in virally suppressed HIV persons. Females were found to be four times more likely to be affected than men. Patients undergoing NNRTI treatments faced higher odds compared to those on INSTI treatments. A low mean corpuscular volume, suggesting microcytosis, was associated to a sixteen-times increase in odds when compared with Normocytosis and Macrocytosis. A lower lymphocyte count was associated with a higher odds of moderate to severe anaemia in HIV. While being on ART treatment for more than 4years was associated with higher odds of moderate to severe anaemia in this study cohort.

On multivariable analysis, females were found to have a significantly higher odds of moderate to severe anaemia than men, with an odds ratio (OR 2.65). A lower lymphocyte count was associated with higher odds (OR 0.54) of moderate to severe anaemia. Higher Body Mass Index (BMI) also increased the odds, albeit slightly, with an OR of 1.062. A low mean corpuscular volume (MCV), suggestive microcytic anaemia, was strongly (OR 14.4) associated with a moderate to severe anaemia. Additionally, patients on non-nucleoside reverse transcriptase inhibitors (NNRTIs) had a 5.16 times higher chance of developing anaemia compared to those on integrase strand transfer inhibitors (INSTIs). Interestingly, traditional risk factors for anaemia among HIV patients, such as CD4+ count and TB infection, were not significant in this study cohort.

Table 2. Factors associated with Moderate to severe anaemia

Variables	Unadjusted Odds ratio		P value	Adjusted Odds		P value
	OR	95%CI		AOR	95%CI	
Age	0.99	0.97-1.01	0.255	1.008	0.98- 1.04	0.587
Sex, Female vs Male	4.14	2.45 -6.98	<0.001	2.647	1.21-5.81	0.015
BMI (kg/m2)	1.04	0.98 -1.05	0.439	1.061	1.01-1.12	0.018
Regimen						
INSTI (DTG)	1					
PI (LPV/r&ATZ/r)	0.88	0.18 -4.43	0.878	1.402	0.21 - 9.37	0.727
NNRTI (EFV&NVP)	3.07	1.39 - 6.77	0.005	5.161	1.02- 26.24	0.048
Duration on ART						
Year 1	1					
Year 2	3.42	1.49 - 0.66	0.339	0.893	0.16- 4.92	0.897
Year 3	1.78	0.95 -3.35	0.074	0.286	0.05 - 1.82	0.185
>4yrs	2.95	1.46-5.93	0.002	0.523	0.14 - 2.00	0.344
Microcytosis, yes	16.45	9.05-29.89	<0.001	14.35	7.33 - 28.08	<0.001
CD4 Count (cell/ul)	1.00	0.99-1.00	0.667	1.00	0.99 -1.00	0.998
Lymphocytes	0.59	0.39-0.88	0.009	0.542	0.33 - 0.90	0.019
Viral load	1.00	0.99 - 1.00	0.619	1.00	0.99 - 1.00	0.799
Tuberculosis, yes	1.08	0.65-1.78	0.773			
HBsAg, yes	2.02	0.71 - 5.71	0.186			
Syphilis, yes	1.54	0.85 - 2.78	0.154			

Discussion:

The study reveals that 29.4% and 14.2% of virally suppressed individuals with HIV who are on ART had anaemia and moderate-to-severe anaemia, respectively. This indicates that, despite effective viral control, anaemia continues to be a prevalent issue, particularly affecting females. The findings are consistent with other research, which shows a broad range of anaemia prevalence, from 7% to 95%, among those treated with ART depending on the clinical context and geographic setting [3], [14]. A study from China showed a decreasing trend in anaemia prevalence over time among a large cohort after initiating ART, yet our study shows that the prevalence remains significantly high. Their study shows a prevalence of anaemia among 436,658 PLWH initiating ART was 29%, and annually, this prevalence reduced to 17.0%, 14.1%, 13.4%, 12.6%, and 12.7%, respectively [15]. The prevalence observed in this study was slightly lower than the prevalence reported in the Ethiopian study (33%) among females, which specifically focused on PLWH on ART. Both studies, however, did not report on the virologic status of their participants [16]. Our study emphasizes the ongoing need to address factors contributing to anaemia, such as nutritional deficiencies, persistent low-grade inflammation, and ART-related toxicities, to improve clinical outcomes for PLWH. Further research is necessary to explain the evolving epidemiology of anaemia in the context of HIV infection and to evaluate the impact of ART on anaemia.

The observation of females having significantly higher odds of moderate-to-severe anaemia compared to males aligns with previous studies in HIV populations. Females are most likely to experience iron deficiency and subsequent anaemia. Female sex hormones may influence erythropoiesis and iron utilization [10], [17].

The inverse relationship between lymphocyte count and moderate-to-severe anaemia suggests that immune status remains a crucial factor in the health of PLWH, even when viral suppression is achieved. Lymphocyte depletion could contribute to anaemia through various mechanisms, including dysregulated cytokine signalling leading to impaired iron metabolism [18]. Surprisingly, CD4+ count did not show significant associations, but effective antiretroviral therapy (ART) and viral suppression may lead to CD4+ cell count recovery [19].

The positive association between higher BMI and moderate-to-severe anaemia is to a certain extent contradictory to expectations, as obesity is often associated with increased iron stores [20]. However, Elevated BMI is linked to chronic inflammation and altered adipokine secretion, affecting erythropoiesis [21]. Furthermore, comorbid conditions commonly associated with obesity, such as chronic kidney disease, could also contribute to anaemia risk. Addressing obesity-related inflammation and iron status is crucial.

Our study found a strong association between low Mean Corpuscular Volume (MCV) and moderate-to-severe anaemia when compared to normocytic and macrocytic anaemia. Additionally, MCV shows a strong correlation with Mean Corpuscular Hemoglobin (MCH), suggesting a pattern consistent with microcytic hypochromic anaemia a classic presentation of iron-deficiency anemia and anaemia chronic disease [22]. Factors such as inadequate dietary intake, malabsorption, chronic bleeding and chronic inflammation may exacerbate iron deficiency anaemia among PLWH in limited settings.

NNRTIs were associated with higher odds of moderate-to-severe anaemia compared to INSTIs (DTG-based regimen). Some NNRTIs may suppress bone marrow function, affecting erythropoiesis but the exact mechanisms underlying this association are not fully elucidated [23]. However, NNRTIs have been implicated in bone marrow suppression due to ART-associated mitochondrial toxicity, which could contribute to decreased erythropoiesis [24], [25]. Long-term effects, including the potential for haematological complications, must be carefully considered.

This study has several limitations that warrant consideration. The cross-sectional design restricts the ability to establish causality between variables, necessitating caution in interpreting the observed associations. The study did not account for some possible causes of anaemia, such as nutritional factors (serum iron, folate and vitamin B12). Strengths of the study include its robust methodology, which employed standardized data collection tools and laboratory measurements, enhancing the reliability of the findings. The inclusion of a large sample size adds to the study's statistical power and allows for precise estimation. The participants in this cohort had achieved virologic suppression, below 1000 cells/uL, mitigating the potential effects of virologic failure.

The findings from this study have significant clinical implications for PLWH. Firstly, the observed prevalence of anaemia and moderate-to-severe anaemia highlights the need for clinicians to pay attention to hematological parameters in this population, even when viral load is well controlled. Secondly, the identification of risk factors such as female gender, low lymphocyte count, high BMI, and specific antiretroviral therapy (ART) regimens provides valuable insights for health professionals and policy makers to tailor interventions accordingly. By addressing these factors, healthcare providers can optimize anaemia management, potentially improving patient outcomes, quality of life, and overall health.

Conclusion: These findings expand upon existing literature on anaemia in HIV-infected populations and adds knowledge to the evolving dynamics of PLWH on treatment. We found a higher prevalence of anaemia (29%) and moderate-to-severe anaemia (14.2%) in virally suppressed PLWH, suggesting that factors beyond HIV contribute to the persistence of anaemia in our cohort; and it was significantly associated with sex, immunological, nutritional, and ART factors. We found that Female gender, lower lymphocyte count, higher BMI, low mean corpuscular volume, and NNRTI-based ART regimens were independently associated with moderate-to-severe anaemia. Understanding these factors allows healthcare providers to proactively manage and prevent moderate-to-severe anaemia among PLWH. There is a need to conduct longitudinal studies to understand the risk factors of moderate-to-severe among virally suppressed PLWH on ART.

Competing interests:

The authors have declared that no competing interests exist.

Funding:

This study received no external funding to conduct this study

References

- [1] M. S. Saag *et al.*, 'Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society–USA Panel', *JAMA*, vol. 324, no. 16, pp. 1651–1669, Oct. 2020, doi: 10.1001/jama.2020.17025.
- [2] UNAIDS, 'Global HIV & AIDS statistics — Fact sheet'. Accessed: Sep. 30, 2023. [Online]. Available: <https://www.unaids.org/en/resources/fact-sheet>
- [3] G. Cao, Y. Wang, Y. Wu, W. Jing, J. Liu, and M. Liu, 'Prevalence of anemia among people living with HIV: A systematic review and meta-analysis', *EClinicalMedicine*, vol. 44, p. 101283, Jan. 2022, doi: 10.1016/j.eclinm.2022.101283.
- [4] M. Araújo-Pereira *et al.*, 'Relationship Between Anemia and Systemic Inflammation in People Living With HIV and Tuberculosis: A Sub-Analysis of the CADIRIS Clinical Trial', *Front. Immunol.*, vol. 13, p. 916216, Jun. 2022, doi: 10.3389/fimmu.2022.916216.
- [5] A. I. Abioye, C. T. Andersen, C. R. Sudfeld, and W. W. Fawzi, 'Anemia, Iron Status, and HIV: A Systematic Review of the Evidence', *Adv. Nutr.*, vol. 11, no. 5, pp. 1334–1363, May 2020, doi: 10.1093/advances/nmaa037.
- [6] P. A. Volberding *et al.*, 'Anemia in HIV Infection: Clinical Impact and Evidence-Based Management Strategies', *Clin. Infect. Dis.*, vol. 38, no. 10, pp. 1454–1463, May 2004, doi: 10.1086/383031.
- [7] K. Kamvuma, B. M. Hamooya, S. Munsaka, S. K. Masenga, and A. Kirabo, 'Mechanisms and Cardiorenal Complications of Chronic Anemia in People with HIV', *Viruses*, vol. 16, no. 4, Art. no. 4, Apr. 2024, doi: 10.3390/v16040542.
- [8] T. Lv, W. Cao, and T. Li, 'HIV-Related Immune Activation and Inflammation: Current Understanding and Strategies', *J. Immunol. Res.*, vol. 2021, p. e7316456, Sep. 2021, doi: 10.1155/2021/7316456.
- [9] G. Weiss, T. Ganz, and L. T. Goodnough, 'Anemia of inflammation', *Blood*, vol. 133, no. 1, pp. 40–50, Jan. 2019, doi: 10.1182/blood-2018-06-856500.
- [10] B. N. Harding *et al.*, 'Anemia risk factors among people living with HIV across the United States in the current treatment era: a clinical cohort study', *BMC Infect. Dis.*, vol. 20, no. 1, p. 238, Mar. 2020, doi: 10.1186/s12879-020-04958-z.
- [11] J. Turner, M. Parsi, and M. Badireddy, 'Anemia', in *StatPearls*, Treasure Island (FL): StatPearls Publishing, 2024. Accessed: Apr. 11, 2024. [Online]. Available: <http://www.ncbi.nlm.nih.gov/books/NBK499994/>
- [12] 'August-2022-Zambia-Consolidated-Guidelines.pdf'. Accessed: Apr. 28, 2024. [Online]. Available: <https://www.differentiatedservicedelivery.org/wp-content/uploads/August-2022-Zambia-Consolidated-Guidelines.pdf>
- [13] 'Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity'. Accessed: Mar. 28, 2024. [Online]. Available: <https://www.who.int/publications-detail-redirect/WHO-NMH-NHD-MNM-11.1>

- [14] N. Zhang, X. Li, L. Ma, Y. Liang, X. Liu, and F. Zhou, 'Prevalence Trends of Anemia Impairment in Adolescents and Young Adults with HIV/AIDS', *Blood*, vol. 142, no. Supplement 1, p. 5192, Nov. 2023, doi: 10.1182/blood-2023-174027.
- [15] L. Wei *et al.*, 'The burden of anemia among Chinese HIV-infected patients following the initiation of antiretroviral therapy in the treat-all era: a nationwide cohort study', *BMC Infect. Dis.*, vol. 23, no. 1, p. 704, Oct. 2023, doi: 10.1186/s12879-023-08675-1.
- [16] T. H. Hadgu, W. Worku, D. Tetemke, and H. Berhe, 'Undernutrition among HIV positive women in Humera hospital, Tigray, Ethiopia, 2013: antiretroviral therapy alone is not enough, cross sectional study', *BMC Public Health*, vol. 13, no. 1, p. 943, Oct. 2013, doi: 10.1186/1471-2458-13-943.
- [17] P. A. Dacks, 'Estrogens Iron Out the Details: A Novel Direct Pathway for Estrogen Control of Iron Homeostasis', *Endocrinology*, vol. 153, no. 7, pp. 2942–2944, Jul. 2012, doi: 10.1210/en.2012-1480.
- [18] B. Xie *et al.*, 'Anemia and opportunistic infections in hospitalized people living with HIV: a retrospective study', *BMC Infect. Dis.*, vol. 22, no. 1, p. 912, Dec. 2022, doi: 10.1186/s12879-022-07910-5.
- [19] T. Fiseha, H. Ebrahim, E. Ebrahim, and A. Gebreweld, 'CD4+ cell count recovery after initiation of antiretroviral therapy in HIV-infected Ethiopian adults', *PLoS ONE*, vol. 17, no. 3, p. e0265740, Mar. 2022, doi: 10.1371/journal.pone.0265740.
- [20] N. M. Alshwaiyat, A. Ahmad, W. M. R. Wan Hassan, and H. A. N. Al-Jamal, 'Association between obesity and iron deficiency (Review)', *Exp. Ther. Med.*, vol. 22, no. 5, p. 1268, Nov. 2021, doi: 10.3892/etm.2021.10703.
- [21] T. V. Kirichenko, Y. V. Markina, A. I. Bogatyreva, T. V. Tolstik, Y. R. Varaeva, and A. V. Starodubova, 'The Role of Adipokines in Inflammatory Mechanisms of Obesity', *Int. J. Mol. Sci.*, vol. 23, no. 23, Art. no. 23, Jan. 2022, doi: 10.3390/ijms232314982.
- [22] A. E. Donker *et al.*, 'Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or heme synthesis', *Blood*, vol. 123, no. 25, pp. 3873–3886, Jun. 2014, doi: 10.1182/blood-2014-01-548776.
- [23] A. L. Caulier and V. G. Sankaran, 'Molecular and cellular mechanisms that regulate human erythropoiesis', *Blood*, vol. 139, no. 16, pp. 2450–2459, Apr. 2022, doi: 10.1182/blood.2021011044.
- [24] M. D. Raphael J. Landovitz, 'NRTI-Associated Mitochondrial Toxicity', *NEJM J. Watch*, vol. 2001, May 2001, doi: 10.1056/AC200105010000007.
- [25] 'Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors - UpToDate'. Accessed: Apr. 11, 2024. [Online]. Available: <https://www.uptodate.com/contents/mitochondrial-toxicity-of-hiv-nucleoside-reverse-transcriptase-inhibitors>